You have 9 free searches left this month | for more free features.

Interleukin 15

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Esophageal Cancer, Pancreas Cancer, Ovarian Cancer Trial in Edegem (IL15-transpresenting WT1-targeted Dendritic Cell Vaccine)

Not yet recruiting
  • Esophageal Cancer
  • +3 more
  • IL15-transpresenting WT1-targeted Dendritic Cell Vaccine
  • Edegem, Belgium
    Antwerp University Hospital
Jul 19, 2023

Neuroblastoma Trial in Houston (GINAKIT Cells, Cyclophosphamide, Fludarabine)

Active, not recruiting
  • Neuroblastoma
  • GINAKIT Cells
  • +2 more
  • Houston, Texas
    Texas Children's Hospital
Jan 18, 2023

Adult T-Cell Lymphoma/Leukemia, Sezary Syndrome, Mycosis Fungoides Trial run by the NCI (Recombinant human Interleukin-15

Completed
  • Adult T-Cell Lymphoma/Leukemia
  • +2 more
  • Recombinant human Interleukin-15 (rhIL-15)
  • Mogamulizumab
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Dec 9, 2022

Active Non Segmental Vitiligo Trial in Cairo (Narrow band ultraviolet B)

Completed
  • Active Non Segmental Vitiligo
  • Narrow band ultraviolet B
  • Cairo, Helwan, Egypt
    Nourhan Emad
Aug 8, 2022

Vitiligo Trial (Interleukin-15 and Interleukin-22)

Not yet recruiting
  • Vitiligo
  • Interleukin-15 and Interleukin-22
  • (no location specified)
Nov 14, 2021

Liver Cell Carcinoma Trial in Houston (CATCH T cells, Cytoxan, Fludara)

Recruiting
  • Liver Cell Carcinoma
  • +7 more
  • CATCH T cells
  • +2 more
  • Houston, Texas
    Houston Methodist Hospital
Dec 19, 2022

Leukemia, Lymphocytic, Chronic Trial run by the NCI (rhIL-15, Obinutuzumab)

Terminated
  • Leukemia
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Mar 11, 2022

Clear-Cell Renal Carcinoma Trial run by the NCI (rhIL-15, Avelumab)

Terminated
  • Clear-Cell Renal Carcinoma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Apr 27, 2022

HIV/AIDS Trial in Bangkok (N-803)

Recruiting
  • HIV/AIDS
  • Bangkok, Thailand
    Thai Red Cross AIDS Research Centre
Oct 4, 2021

Liver Cancer, Rhabdomyosarcoma, Malignant Rhabdoid Tumor Trial in Houston (CARE T cells, Cytoxan, Fludara)

Not yet recruiting
  • Liver Cancer
  • +5 more
  • CARE T cells
  • +2 more
  • Houston, Texas
    Texas Children's Hospital
Dec 1, 2021

Lynch Syndrome Trial in Puerto Rico, United States (procedure, drug, other, biological)

Not yet recruiting
  • Lynch Syndrome
  • Biopsy
  • +5 more
  • Phoenix, Arizona
  • +13 more
Sep 16, 2022

Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma Trial in Boston (Interleukin-15

Recruiting
  • Squamous Cell Carcinoma of the Head and Neck
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • Interleukin-15 Superagonist (N-803)
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Dec 2, 2022

T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL), Peripheral T-Cell Lymphoma (PTCL) Trial run by the NCI (IL-15 plus,

Completed
  • T-Cell Lymphoma Relapsed
  • +4 more
  • IL-15 plus
  • alemtuzumab
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Apr 27, 2022

NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia Trial (KUR-502)

Not yet recruiting
  • NHL, Relapsed, Adult
  • +3 more
  • KUR-502
  • (no location specified)
Aug 2, 2022

Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Small Lymphocytic Lymphoma, Relapsed Adult ALL Trial in Houston

Recruiting
  • Refractory B-Cell Non-Hodgkin Lymphoma
  • +4 more
  • CD19.CAR-aNKT cells
  • +2 more
  • Houston, Texas
  • +1 more
Aug 19, 2022

Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma Trial in United States (NKTR-255 at 1.5 µg/kg, NKTR-255

Recruiting
  • Non-Hodgkin Lymphoma
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma
  • NKTR-255 at 1.5 µg/kg
  • +3 more
  • La Jolla, California
  • +26 more
Jan 10, 2023

Hepatocellular Carcinoma, Hepatoblastoma Trial (TEGAR T cells, Cytoxan, Fludarabine)

Withdrawn
  • Hepatocellular Carcinoma
  • Hepatoblastoma
  • TEGAR T cells
  • +2 more
  • (no location specified)
May 19, 2020

Melanoma Trial in Houston (HDIL-2, recMAGE-A3 + AS15)

Completed
  • Melanoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Feb 17, 2020

Acute Myeloid Leukemia, Leukemia, Leukemia, Myeloid Trial in Boston (Cytokine Induced Memory-like Natural Killer Cells,

Not yet recruiting
  • Acute Myeloid Leukemia
  • +5 more
  • Cytokine Induced Memory-like Natural Killer Cells
  • Interleukin-2
  • Boston, Massachusetts
  • +1 more
Nov 14, 2023

Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Soft Palate Trial in Worldwide (biological, drug,

Completed
  • Squamous Cell Carcinoma of the Oral Cavity
  • Squamous Cell Carcinoma of the Soft Palate
  • LI
  • +6 more
  • Springfield, Illinois
  • +101 more
Aug 17, 2022

Renal Cell Carcinoma Trial in United States (Entinostat, Interleukin-2)

Active, not recruiting
  • Renal Cell Carcinoma
  • Los Angeles, California
  • +4 more
Feb 14, 2022

Neuroblastoma, Osteosarcoma Trial in Chapel Hill (iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, Fludarabine)

Recruiting
  • Neuroblastoma
  • Osteosarcoma
  • iC9.GD2.CAR.IL-15 T-cells
  • +2 more
  • Atlanta, Georgia
  • +1 more
Jan 4, 2023

Lymphocytes, Tumor-Infiltrating Trial in Saint Petersburg (Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide,

Not yet recruiting
  • Lymphocytes
  • Tumor-Infiltrating
  • Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide, Interleukin-2
  • Saint Petersburg, Florida
  • +1 more
Sep 15, 2023

Burnout Syndrome, Neutrophil-Lymphocyte Ratio, Interleukin-6 Trial (music therapy)

Not yet recruiting
  • Burnout Syndrome
  • +3 more
  • music therapy
  • (no location specified)
Feb 20, 2023

Metastatic Melanoma, Unresectable Melanoma, Acral Melanoma Trial in Tampa (TBio-4101, Cyclophosphamide, Fludarabine)

Recruiting
  • Metastatic Melanoma
  • +9 more
  • TBio-4101
  • +3 more
  • Tampa, Florida
    Moffitt Cancer Center
Jan 24, 2023